Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Endocrine therapy for desmoid tumors.

N Wilcken¹, M H Tattersall

¹Department of Medical Oncology, Royal Prince Alfred Hospital, Sydney, Australia.

|September 15, 1991

Summary

Endocrine therapy, including tamoxifen and Zoladex, can lead to tumor regression in desmoid tumors (aggressive fibromatosis). This approach shows promise for inoperable cases and those with recurrence, with a 51% response rate in literature.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study.

Brain, behavior, & immunity - health·2021

Same author

More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials.

Breast (Edinburgh, Scotland)·2016

Same author

Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2015

Same author

Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital.

Internal medicine journal·2014

Same author

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).

Breast (Edinburgh, Scotland)·2014

Same author

Post-cancer fatigue is not associated with immune activation or altered cytokine production.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Area of Science:

Oncology
Endocrinology
Surgical Pathology

Background:

Desmoid tumors, also known as aggressive fibromatosis, are rare fibroblastic neoplasms.
Their biology is increasingly understood to be influenced by the endogenous hormonal environment, with estrogen receptors identified in tumor tissues.

Observation:

Two female patients with desmoid tumors experienced significant tumor regression following endocrine therapy.
One patient achieved sustained response with tamoxifen over several years.
A second patient with inoperable mesenteric fibromatosis progressed on tamoxifen but responded to Zoladex (goserelin acetate) and medroxyprogesterone acetate (MPA).

Findings:

This study reports the first known use of Zoladex for desmoid tumors.
A literature review identified 35 cases of endocrine agent use for desmoid tumors, yielding a 51% response rate.
Tumors demonstrated potential to respond to second-line hormonal therapy after initial treatment failure.

Implications:

Endocrine therapy is recommended for inoperable desmoid tumors or post-surgical recurrence.
Further research should explore the role of endocrine therapy in other soft tissue neoplasms.
Hormonal modulation represents a viable therapeutic strategy for specific fibroblastic disorders.

Related Experiment Videos